Literature DB >> 11458818

Magnetic resonance imaging and spectroscopic imaging of prostate cancer.

M G Swanson1, D B Vigneron, T K Tran, J Kurhanewicz.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11458818     DOI： 10.1081/cnv-100103849

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  6 in total

1.  Multimodal wavelet embedding representation for data combination (MaWERiC): integrating magnetic resonance imaging and spectroscopy for prostate cancer detection.

Authors:  P Tiwari; S Viswanath; J Kurhanewicz; A Sridhar; A Madabhushi
Journal:  NMR Biomed       Date:  2011-09-30       Impact factor: 4.044

2.  Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.

Authors:  K R Keshari; H Tsachres; R Iman; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

3.  In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.

Authors:  Youngho Seo; Carina Mari Aparici; Matthew R Cooperberg; Badrinath R Konety; Randall A Hawkins
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 4.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

5.  Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.

Authors:  Mark G Swanson; Kayvan R Keshari; Z Laura Tabatabai; Jeffry P Simko; Katsuto Shinohara; Peter R Carroll; Andrew S Zektzer; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2008-07       Impact factor: 4.668

6.  Validation of the dosimetric and geometric accuracy of MR-only treatment planning solution for prostate cancer radiotherapy.

Authors:  Michał Posiewnik; Tomasz Piotrowski
Journal:  Contemp Oncol (Pozn)       Date:  2022-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.